Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
ASCO 2020 - Lung Cancer
ASCO 2020 - Lung Cancer
Combination of Nivolumab, Ipilimumab, and Chemotherapy in Metastatic NSCLC
ASCO 2020 - Lung Cancer
Combining nivolumab plus ipilimumab with 2 cycles of chemotherapy may be effective in patients undergoing first-line treatment for metastatic non–small-cell lung cancer.
Read More
3-Year Follow-Up Data for Nivolumab Combined with Ipilimumab in Treatment-Naïve NSCLC: CheckMate-227
ASCO 2020 - Lung Cancer
After 3 years of follow-up, nivolumab combined with ipilimumab demonstrates sustained overall survival rates in treatment-naïve patients with advanced non–small-cell lung cancer.
Read More
CheckMate-9LA Evaluates Addition of Chemotherapy to NIVO + IPI in First-Line Advanced NSCLC
ASCO 2020 - Lung Cancer
The addition of 2 cycles of chemotherapy to the combination of nivolumab and ipilimumab results in superior overall survival in treatment-naïve patients with advanced non–small-cell lung cancer.
Read More
Real-World Data for Nivolumab in Patients with Malignant Mesothelioma
ASCO 2020 - Lung Cancer
Standard treatment for patients with advanced malignant pleural mesothelioma is predominantly chemotherapy-based. Nivolumab may be effective in these patients based on a retrospective real-world data assessment.
Read More
Immunotherapy Combined with Stereotactic Radiation in Early-Stage, Medically Inoperable NSCLC: Safety Analysis from I-SABR
ASCO 2020 - Lung Cancer
Stereotactic ablative radiotherapy combined with immunotherapy (I-SABR) is well-tolerated in patients with early-stage, medically inoperable, isolated-recurrence non–small-cell lung cancer without lymph node or distant metastasis.
Read More
Meta-analysis of Checkpoint Inhibitor Trials in Front-Line NSCLC
ASCO 2020 - Lung Cancer
Based on a meta-analysis of randomized trials in the first-line treatment of non–small-cell lung cancer, adding chemotherapy to immune checkpoint inhibitors (ICIs) improves response rates and progression-free survival in some patients compared with ICI monotherapy, but does not confer an overall survival benefit regardless of PD-L1 status.
Read More
Page 2 of 2
1
2
This ASCO 2020 conference coverage is supported through funding by
View the Latest Issue of VBCC
Read Issue
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma